Send the following on WhatsApp
Continue to ChatAccording to the NCI website, ALLO-647 is a monoclonal antibody directed against the cell surface glycoprotein CD52 (CAMPATH-1 antigen; Cambridge pathology 1 antigen), with potential immunodepleting activity. Upon administration, anti-CD52 monoclonal antibody ALLO-647 selectively targets and binds to CD52, thereby … https://oncoletter.ch/krebstherapie/alle-wirkstoffe/wirkstoff/allo-647.html